Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Tectonic Therapeutic, Inc. has seen a significant stock rally which has seen its shares nearly triple since this summer. What ...

Certa Therapeutics Pty Ltd. has acquired Occurx Pty Ltd. in a move to strengthen its pipeline to target multiple fibrotic diseases as both companies share a focus on targeting GPR68, a defined G ...

Kaken will take the drug through phase I trials, after which J&J takes over. Under the terms, Kaken banks an up-front payment of $30 million and could collect more than $1.2 billion if development and ...

Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with ...

Exicure, Inc. , has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. ("GPCR Therapeutics") on December 24, 2024, aimed at the acquisition of GPCR USA, a ...

Breast cancer remains a leading health crisis worldwide, claiming the lives of approximately 685,000 women in 2020 alone.

Fintel reports that on December 23, 2024, D. Boral Capital initiated coverage of Omeros (NasdaqGM:OMER) with a Buy ...

Dis new pathway go allow migrants and dia families to come live permanently for Australia. Di National Innovation visa dey replace di Global Talent visa wey end for 6 December. According to di ...

This demonstrates the utility of DMS for various drug discovery and development applications, and the methods described herein should be broadly applicable to GPCRs and other drug target classes that ...

Almost 35% of drugs approved by the Food and Drug Administration work by targeting G protein-coupled receptors (GPCRs), proteins embedded in cell membranes that allow cells to communicate with ...

Protein kinases and G-protein coupled receptors (GPCRs) are key targets in chemical biology research due to their significance in signaling pathways and physiological processes. Achieving selectivity ...